R&D channel feed – Endpoints News

R&D channel feed

Sanofi, Regeneron boast PhIII win with Dupixent in COPD, clearing first bar for expansion

3 years ago

Regeneron scores label expansion for cholesterol drug Evkeeza

3 years ago

Novartis pulls the plug on UK-based cardiovascular study

3 years ago

FDA rejects AbbVie's infusion therapy for Parkinson's, requests more info on pump device

3 years ago

Quince Therapeutics faces takeover bid from shareholder Echo Lake Capital

3 years ago

Astellas fleshes out more PhIII data for Claudin 18.2 drug

3 years ago

Novartis touts seven years of durability data for Zolgensma

3 years ago

Roche and Lilly team up to develop blood test to detect early signs of Alzheimer's

3 years ago

89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround

3 years ago

Immatics announces multiple pipeline changes with latest financial results

3 years ago

Roche unveils long-term data from pivotal spinal muscular atrophy trial

3 years ago

Altimmune’s shares halved after interim look at PhII weight loss drug data

3 years ago

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

3 years ago

Sobi's PhIII gout win sets up a potential rivalry with future Amgen asset

3 years ago

FDA indicates willingness to approve Biogen ALS drug despite failed PhIII study

3 years ago

Athenex discloses patient death, clinical hold on CAR-NKT trial as it seeks strategic alternatives

3 years ago

Karuna’s schizophrenia drug clears another PhIII as biotech seeks 2024 launch

3 years ago

What kind of PhIIb data is worth $4B cash? Takeda’s Andy Plump has some thoughts on that

3 years ago

Gossamer stops enrollment on BTK inhibitor program, goes all in on PAH drug

3 years ago

Pfizer, Astellas tout positive PhIII data to potentially expand Xtandi label

3 years ago

Merck's Keytruda plus TIGIT combo proves less effective than chemo in open-label lung cancer study

3 years ago

'Very real' headwinds: With leaner staff, cancer vaccine maker searches for help

3 years ago

In ‘surprise’ move, BioXcel files for cancer subsidiary to go public

3 years ago

Esperion stock halved after Daiichi discord over $440M heart pill milestones

3 years ago

First page Previous page 92 93 949596 97 98 Next page Last page